Web-based portal may improve quality of adverse event reports
This article was originally published in The Silver Sheet
Executive Summary
FDA and the National Institutes of Health have entered into a memorandum of understanding that aims to deliver a centralized Web-based portal for adverse event reporting that may improve report quality, lower costs and reduce delivery time. Both agencies already are working on their own revamped adverse event reporting systems. FDA has its long-term sights on a single, agency-wide electronic portal - dubbed MedWatch Plus - for collecting adverse events, consumer complaints and other information relating to all products it regulates. NIH has created the Federal Adverse Event Task Force (of which FDA is a part) to develop a portal designed so clinical trial adverse events can be reported in a single, standardized format. With the MOU, the agencies are combining efforts. "NIH and FDA aim to develop a project that will result in a Web-based method for consumers, health professionals, investigators, sponsors and other parties to electronically submit [adverse event] reports," the memorandum states
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.